Published in Drug Discov Today on May 13, 2016
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
The future of immune checkpoint therapy. Science (2015) 5.59
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (2014) 5.42
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2014) 3.94
The present and future role of microfluidics in biomedical research. Nature (2014) 3.32
Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng (2003) 3.04
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 2.86
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Current concepts in the diagnosis and management of cytokine release syndrome. Blood (2014) 2.63
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science (2015) 2.50
Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol (2004) 2.49
Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc Natl Acad Sci U S A (2012) 2.29
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014) 2.25
Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol (2014) 2.22
Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol (2007) 1.92
T cell exclusion, immune privilege, and the tumor microenvironment. Science (2015) 1.88
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
3D Cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayer. PLoS One (2014) 1.54
Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials (2009) 1.54
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res (2013) 1.47
Developers seek to finetune toxicity of T-cell therapies. Nat Biotechnol (2014) 1.47
Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol (2010) 1.38
A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone. Biomaterials (2013) 1.34
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A (2012) 1.30
Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther (2007) 1.27
New dimensions in tumor immunology: what does 3D culture reveal? Trends Mol Med (2008) 1.22
Mechanisms of tumor cell extravasation in an in vitro microvascular network platform. Integr Biol (Camb) (2013) 1.19
Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. Integr Biol (Camb) (2013) 1.17
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov (2015) 1.14
A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev (2014) 1.14
Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc Natl Acad Sci U S A (2014) 1.13
A microfluidic-based device for study of transendothelial invasion of tumor aggregates in realtime. Lab Chip (2012) 1.12
Cellular capsules as a tool for multicellular spheroid production and for investigating the mechanics of tumor progression in vitro. Proc Natl Acad Sci U S A (2013) 1.08
Engineering of in vitro 3D capillary beds by self-directed angiogenic sprouting. PLoS One (2012) 1.04
Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models. PLoS One (2013) 1.04
A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids (2013) 0.99
Microfluidic model of ductal carcinoma in situ with 3D, organotypic structure. BMC Cancer (2015) 0.96
Physicochemical regulation of endothelial sprouting in a 3D microfluidic angiogenesis model. J Biomed Mater Res A (2013) 0.95
3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitro. Adv Healthc Mater (2012) 0.92
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev (2014) 0.92
The effects of time and intensity of exercise on novel and established markers of CVD in adolescent youth. Am J Hum Biol (2011) 0.91
Combinatorial guidance by CCR7 ligands for T lymphocytes migration in co-existing chemokine fields. PLoS One (2011) 0.91
Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and β2 integrin interactions. Oncotarget (2015) 0.88
Impact of human bladder cancer cell architecture on autologous T-lymphocyte activation. Int J Cancer (2002) 0.87
A microfluidic platform for quantitative analysis of cancer angiogenesis and intravasation. Biomicrofluidics (2014) 0.86
Use of amplicon-6 vectors derived from human herpesvirus 6 for efficient expression of membrane-associated and -secreted proteins in T cells. J Virol (2004) 0.85
Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes. Br J Cancer (2007) 0.85
Three-dimensional scaffolds to evaluate tumor associated fibroblast-mediated suppression of breast tumor specific T cells. Biomacromolecules (2013) 0.84
An in vitro model of the tumor-lymphatic microenvironment with simultaneous transendothelial and luminal flows reveals mechanisms of flow enhanced invasion. Integr Biol (Camb) (2015) 0.84
Rapid prototyping of concave microwells for the formation of 3D multicellular cancer aggregates for drug screening. Adv Healthc Mater (2013) 0.84
Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. Tumour Biol (2015) 0.83
Inflammatory mimetic microfluidic chip by immobilization of cell adhesion molecules for T cell adhesion. Analyst (2012) 0.82
Patient-specific 3D microfluidic tissue model for multiple myeloma. Tissue Eng Part C Methods (2014) 0.82
Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells? Clin Exp Metastasis (2013) 0.82
A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma. Lab Chip (2013) 0.82
Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays. Gynecol Oncol (2015) 0.82
A microfluidic model for organ-specific extravasation of circulating tumor cells. Biomicrofluidics (2014) 0.81
Evaluation of photodynamic therapy efficiency using an in vitro three-dimensional microfluidic breast cancer tissue model. Lab Chip (2015) 0.81
The migration speed of cancer cells influenced by macrophages and myofibroblasts co-cultured in a microfluidic chip. Integr Biol (Camb) (2011) 0.81
High-throughput 3D cell invasion chip enables accurate cancer metastatic assays. J Am Chem Soc (2014) 0.81
A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials (2015) 0.81
A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs. Lab Chip (2015) 0.81
Modeling of cancer metastasis and drug resistance via biomimetic nano-cilia and microfluidics. Biomaterials (2013) 0.80
Complementary effects of ciclopirox olamine, a prolyl hydroxylase inhibitor and sphingosine 1-phosphate on fibroblasts and endothelial cells in driving capillary sprouting. Integr Biol (Camb) (2013) 0.79
Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment. Oncotarget (2015) 0.79
Establishment of a heterotypic 3D culture system to evaluate the interaction of TREG lymphocytes and NK cells with breast cancer. J Immunol Methods (2015) 0.78
Screening candidate metastasis-associated genes in three-dimensional HCC spheroids with different metastasis potential. Int J Clin Exp Pathol (2014) 0.77
Using microfluidics to investigate tumor cell extravasation and T-cell immunotherapies. Conf Proc IEEE Eng Med Biol Soc (2015) 0.76